Akari Therapeutics Plc
No enriched coverage for $AKTX in the last 7 days.
No SEC Form 4 filings for $AKTX in the last 30 days.
See all $AKTX insider activity →Akari Therapeutics (AKTX) increased CEO Abizer Gaslightwala's base salary to $625,000, raised his bonus target to 55%, and granted options and RSUs. The changes were effective August 18, 2026, with the amendment entered on September 29, 2026. The company did not disclose reasons for the changes.
Akari Therapeutics Plc (AKTX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 29, 2026, Akari Therapeutics, Plc (the “ Company ”), entered into an amendment (the “ CEO Agreement Amendment
Akari Therapeutics (AKTX) filed a patent for its PH1 payload technology targeting cancer cells. The company plans to start a first-in-human trial for AKTX-101 by mid-2027. Preclinical studies showed promising results against various oncogenic drivers. AKTX is developing ADCs with RNA splicing-targeting payloads.
Recent AKTX coverage spans technology, corporate actions and financial news.
Compensation boost may signal confidence in management but unlikely to move the stock materially.
Compensation increase may be viewed as dilution risk and cost rise, potentially weighing on the stock.
The patent filing adds to Akari's IP portfolio and may boost investor sentiment.
The filing may enhance the company's competitive moat and support future valuation, but no immediate price catalyst.
New preclinical results suggest AKTX-101 may address KRAS-driven cancers, potentially unlocking partnership or licensing value.
AlphAI scores every news story that mentions AKTX with an AI model for sentiment and relevance, and aggregates insider trades from Akari Therapeutics Plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Akari Therapeutics (AKTX) increased CEO Abizer Gaslightwala's base salary to $625,000, raised his bonus target to 55%, and granted options and RSUs. The changes were effective August 18, 2026, with the amendment entered on September 29, 2026. The company did not disclose reasons for the changes.
1 min readAkari Therapeutics Plc (AKTX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 29, 2026, Akari Therapeutics, Plc (the “ Company ”), entered into an amendment (the “ CEO Agreement Amendment
1 min readAkari Therapeutics (AKTX) filed a patent for its PH1 payload technology targeting cancer cells. The company plans to start a first-in-human trial for AKTX-101 by mid-2027. Preclinical studies showed promising results against various oncogenic drivers. AKTX is developing ADCs with RNA splicing-targeting payloads.
2 min readAkari Therapeutics (AKTX) filed a PCT patent application for its PH1 payload, which targets RNA splicing in cancers. The filing expands the company's intellectual property portfolio, covering PH1's ability to disrupt multiple cancer-driving pathways. Akari's CEO highlighted PH1's potential to impact angiogenesis, oncogene signaling, and programmed cell death, supporting its use across various cancer types.
2 min readAkari Therapeutics (AKTX) shares rose 50% after CEO highlighted preclinical data for its cancer treatment platform, AKTX-101, showing promise in pancreatic cancer models. The company plans to present data at the ASCO meeting in 2026 and begin Phase 1 trials in mid-2027. AKTX raised $5.5M in private financing. The stock is up 125% YTD.
2 min readU.S. stock indices S&P 500, Nasdaq 100, and Dow Jones hit record highs. Oil prices and Treasury yields eased on U.S.-Iran ceasefire hopes. April's PCE inflation data showed a 3.8% annual increase. IBM plans $10B quantum computing investment. SNOW surged on AWS partnership. LLY rose after CVS restored drug coverage. AKTX highlighted cancer treatment potential. CZR agreed to a $17.6B acquisition.
3 min readAkari Therapeutics reported a Q2 2026 net loss of $4.8M, up from $1.9M a year earlier, and said it ended June 30, 2026 with $7.7M cash. The company raised about $8.6M gross proceeds (about $8.0M net) via private placement and warrant exercises. Akari is advancing AKTX-101 toward a planned mid-2027 Phase 1 start.
1 min readAkari Therapeutics Plc (AKTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform AKTX-101 advancing through IND-enabling development activities toward planned initiation of P
2 min readAkari Therapeutics (AKTX) said it will collaborate with Whitehawk Therapeutics on preclinical studies combining Akari’s PH1 spliceosome-modulating ADC payload with Whitehawk’s TOP1 inhibitor ADC platform. Akari will lead the work to assess dual-payload compatibility and potential synergies. AKTX shares were down 15.07% to $9.10 after a 1-for-40 reverse split on March 30, 2026.
3 min readTwo U.S. biotech firms, Akston Biosciences and OKAVA Pharmaceuticals, are testing experimental GLP-1 weight-loss treatments for overweight cats. Akston is sponsoring a Cornell study of about 70 cats, while OKAVA is trialing a long-acting implant for up to six months. The drugs are unapproved and results are expected later this year.
6 min read
